About

Vico was founded in Q4 2019 by the highly experienced entrepreneurs Luc Dochez and Josh Mandel-Brehm and seasoned scientists Dr. Judith van Deutekom and Dr. Gail Mandel with strong academic reputations and vast industry experience.

Become a recognized leader bringing innovative oligonucleotide based RNA modulating therapeutics to patients suffering from rare CNS disorders.

We foster positive and collaborative relationships with all stakeholders, including patients, academics, physicians and our employees, essential for the development of new therapies for rare CNS disorders.

It is our mission to advance these therapies and our team is committed to realize the full potential of our pipeline and technologies to the benefit of patients.

Our programs are driven by a highly competent and experienced team consisting of molecular biologists, chemists and drug development experts with over a decade of experience in bringing novel therapies into the clinic and to the market.

Management Team

Gertjan Bartlema

Gertjan Bartlema

Chief Executive Officer

Judith van Deutekom

Judith van Deutekom

Managing Director & Chief Scientific Officer

Nicole Datson

Nicole Datson

Chief Development Officer

Anne Bechet

Anne Bechet

Chief Operating Officer

Rupert Sandbrink

Rupert Sandbrink

Chief Medical Officer